胆路系疾患治療に関する臨床的ならびに実験的研究

書誌事項

タイトル別名
  • タンロケイ シッカン チリョウ ニ カンスル リンショウテキ ナラビニ ジッケンテキ ケンキュウ
  • CLINICAL AND EXPERIMENTAL STUDIES ON THERAPY OF BILIARY DISEASES
  • 原著
  • Original Article

この論文をさがす

抄録

type:text

A) Clinical study. This study is based on 164 cases of biliary disease that were admitted to our clinic. The species of microorganism in the bile obtained from the patients, complaints of the patients, effects of medical cure on the inflammatory symptomes, and late results of the patients have been studied. The results are as follows : 1) The effects of medical treatment is influenced by condition of the bile duct rather than applied medical treatment. The applied medical treatment can not change the indication of surgical operation or the prognosis of the patients. 2) The complaints and inflammatory symptomes of most cases due to obstructive causes such as tumor and stone which are hard to remove can not be reduced by medical treatment. 3) In the blood of the patient combined with bacteremia, we detected the same species of microorganism as we found in the bile of the patient. Obstruction of the extrahepatic bile duct and distended bile duct are also noted in the same case as described above. B) Experimental study. 1) In the experimental study of the dog, the effect of choleretica has been considered. The effect of choleretica has been proved to become weak in the order of Dehychol, Zanchol, Yoshichol, Lipotrin, Gallogen, Galulen and Fericur. 2) Concentration of tetracycline in the bile is decreased in a case in which tetracycline and choleretica are used together, in comparison with concentration of tetracycline in the bile in the case in which tetracycline is given individually. 3) In the case in which tetracycline and choleretica were given together, Zanchol, Lipotrin and Yoshichol caused some increase in the level of concentration of tetracycline in the bile after tetracycline was double loaded. This finding seems to suggest exhaustion of the liver caused by using both medicaments together.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ